We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Cause of Warburg Micro Syndrome Identified

By LabMedica International staff writers
Posted on 25 Nov 2013
A gene responsible for Warburg Micro syndrome, a rare genetic disease characterized by eye, brain, and endocrine abnormalities, has been identified by mutation screening.

Patients with Warburg Micro syndrome are severely challenged physically and mentally, unable to learn how to walk or speak, and become blind and paralyzed from an early age. More...


A collaborative team of scientists led by those at the Medical College of Wisconsin (Milwaukee, WI, USA) and the University of Edinburgh (UK) studied a cohort consisting of 77 individuals with a spectrum of Warburg micro syndrome (WARBM) disorders including 59 typical WARBM cases, five with the milder Martsolf syndrome, and 13 atypical cases. Some complementary studies were conducted in a murine model.

Mutation screening of the complete coding region of TBC1 Domain Family, Member 20 (TBC1D20), and three members of the RAS Oncogene Family RAB1A, RAB1B, and RAB2A was performed by direct sequence analysis in both directions by using genomic DNA extracted from venous blood. Real-time polymerase chain reaction (qPCR) analysis of genomic DNA from one individual was carried out on a LightCycler 480 (Roche Applied Science; Indianapolis, IN, USA) with primers designed to amplify coding regions of TBC1D20 as well as the 5′ and 3′ genes RanBP-Type and C3HC4-Type Zinc Finger Containing 1(RBCK1).

Clinical evaluation of individuals carrying pathogenic TBC1D20 mutations was sufficient to conclude that they cause a disease phenotype indistinguishable to that caused by mutations in genes encoding for Rab3 GTPase-activating protein catalytic subunit, RAB3GAP1, RAB3GAP2, or RAB18. The four genes do not comprise the full causative picture for Warburg Micro syndrome; in about half of the cases, the causing mutation was in none of those genes, which means there are additional novel genes contributing to the disease.

Duska J. Sidjanin, PhD, an associate professor of cell biology, neurobiology and anatomy and senior author of the study said, “These findings have implications not only for families affected with Warburg Micro syndrome, but also provide novel information about the genes and molecular pathways essential for human development that is relevant for more common developmental disorders such as epilepsy and autism.” The study was published on November 14, 2013, in the American Journal of Human Genetics.

Related Links:

Medical College of Wisconsin
University of Edinburgh 
Roche Applied Science



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
HPV Test
Allplex HPV28 Detection
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.